摘要
目的 分析糖尿病周围神经病变治疗中胰激肽原酶与依帕司他联合用药的效果。方法 回顾性选取2021年1月-2022年12月单县中心医院糖尿病周围神经病变患者200例,依据用药方法分为联合用药组(联合胰激肽原酶与依帕司他治疗)、单独用药组(单独应用胰激肽原酶治疗),各100例。统计分析两组肌电图指标、神经功能、临床疗效、炎性因子水平、氧化应激反应、不良反应发生情况。结果 联合用药组的腓总神经、正中神经的感觉神经传导速度与运动神经传导速度均高于单独用药组,差异有统计学意义(P<0.05)。联合用药组的感觉功能、神经症状、神经反射评分均低于单独用药组,差异有统计学意义(P<0.05)。联合用药组患者的总有效率高于单独用药组,差异有统计学意义(P<0.05)。联合用药组患者的炎性因子水平、氧化应激反应均优于单独用药组,差异有统计学意义(P<0.05)。两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论 DPN治疗中胰激肽原酶与依帕司他联合用药的效果较胰激肽原酶单独用药更优异。
Objective To analyze the effect of the combination of pancreatic kallidinogenase and epalrestat in the treatment of diabetes peripheral neuropathy.Methods From January 2021 to December 2022,200 patients with(DPN)in Shan County Central Hospital were retrospectively selected.According to the medication method,they were divided into a combined medication group(combined with pancreatic kallidinogenase and epalrestat)and a single medication group(treated with pancreatic kallidinogenase alone),with 100 cases in each group.Statistical analysis of electromyography indicators,neurological function,clinical efficacy,levels of inflammatory factors,oxidative stress reaction,and adverse reactions in the two groups.Results The sensory nerve nerve conduction velocity and motor nerve conduction velocity of the common peroneal nerve and median nerve in the combined drug group were higher than those in the single drug group,and the difference was statistically significant(P<0.05).The scores of sensory function,neurological symptoms and nerve reflex in the combined drug group were lower than those in the single drug group,and the difference was statistically significant(P<0.05).The total effective rate of patients in the combination therapy group was higher than that in the single therapy group,and the difference was statistically significant(P<0.05).The levels of inflammatory factors and oxidative stress response in the combination therapy group were better than those in the single therapy group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups of patients(P>0.05).Conclusion The combined use of pancreatic kallidinogenase and eparastatin in DPN treatment is more effective than pancreatic kallidinogenase alone.
作者
刘效荣
刘镜军
LIU Xiaorong;LIU Jingjun(Department of Endocrinology,Shanxian Central Hospital,Shanxian,Shandong Province,274300 China;Department of Pharmacy,Shanxian Central Hospital,Shanxian,Shandong Province,274300 China)
出处
《糖尿病新世界》
2023年第13期161-164,共4页
Diabetes New World Magazine
关键词
糖尿病周围神经病变
胰激肽原酶
依帕司他
不良反应
Diabetic peripheral neuropathy
Pancreatic kininogenase
Epalrestat
Adverse reaction
作者简介
刘效荣(1983-),女,硕士,副主任医师,研究方向为内分泌与代谢性疾病。
